BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 23254376)

  • 1. Rescue of dendritic spine phenotype in Fmr1 KO mice with the mGluR5 antagonist AFQ056/Mavoglurant.
    Pop AS; Levenga J; de Esch CE; Buijsen RA; Nieuwenhuizen IM; Li T; Isaacs A; Gasparini F; Oostra BA; Willemsen R
    Psychopharmacology (Berl); 2014 Mar; 231(6):1227-35. PubMed ID: 23254376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alterations in CA1 hippocampal synapses in a mouse model of fragile X syndrome.
    Jawaid S; Kidd GJ; Wang J; Swetlik C; Dutta R; Trapp BD
    Glia; 2018 Apr; 66(4):789-800. PubMed ID: 29274095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early continuous inhibition of group 1 mGlu signaling partially rescues dendritic spine abnormalities in the Fmr1 knockout mouse model for fragile X syndrome.
    Su T; Fan HX; Jiang T; Sun WW; Den WY; Gao MM; Chen SQ; Zhao QH; Yi YH
    Psychopharmacology (Berl); 2011 May; 215(2):291-300. PubMed ID: 21181121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic administration of AFQ056/Mavoglurant restores social behaviour in Fmr1 knockout mice.
    Gantois I; Pop AS; de Esch CE; Buijsen RA; Pooters T; Gomez-Mancilla B; Gasparini F; Oostra BA; D'Hooge R; Willemsen R
    Behav Brain Res; 2013 Feb; 239():72-9. PubMed ID: 23142366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rescue of Fmr1
    Westmark PR; Dekundy A; Gravius A; Danysz W; Westmark CJ
    Neurobiol Dis; 2018 Nov; 119():190-198. PubMed ID: 30125640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subregion-specific dendritic spine abnormalities in the hippocampus of Fmr1 KO mice.
    Levenga J; de Vrij FM; Buijsen RA; Li T; Nieuwenhuizen IM; Pop A; Oostra BA; Willemsen R
    Neurobiol Learn Mem; 2011 May; 95(4):467-72. PubMed ID: 21371563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model.
    Bilousova TV; Dansie L; Ngo M; Aye J; Charles JR; Ethell DW; Ethell IM
    J Med Genet; 2009 Feb; 46(2):94-102. PubMed ID: 18835858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fragile X-like behaviors and abnormal cortical dendritic spines in cytoplasmic FMR1-interacting protein 2-mutant mice.
    Han K; Chen H; Gennarino VA; Richman R; Lu HC; Zoghbi HY
    Hum Mol Genet; 2015 Apr; 24(7):1813-23. PubMed ID: 25432536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective Deletion of Astroglial FMRP Dysregulates Glutamate Transporter GLT1 and Contributes to Fragile X Syndrome Phenotypes In Vivo.
    Higashimori H; Schin CS; Chiang MS; Morel L; Shoneye TA; Nelson DL; Yang Y
    J Neurosci; 2016 Jul; 36(27):7079-94. PubMed ID: 27383586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic metabotropic glutamate receptor 5 inhibition corrects local alterations of brain activity and improves cognitive performance in fragile X mice.
    Michalon A; Bruns A; Risterucci C; Honer M; Ballard TM; Ozmen L; Jaeschke G; Wettstein JG; von Kienlin M; Künnecke B; Lindemann L
    Biol Psychiatry; 2014 Feb; 75(3):189-97. PubMed ID: 23910948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delayed stabilization of dendritic spines in fragile X mice.
    Cruz-Martín A; Crespo M; Portera-Cailliau C
    J Neurosci; 2010 Jun; 30(23):7793-803. PubMed ID: 20534828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome.
    Levenga J; Hayashi S; de Vrij FM; Koekkoek SK; van der Linde HC; Nieuwenhuizen I; Song C; Buijsen RA; Pop AS; Gomezmancilla B; Nelson DL; Willemsen R; Gasparini F; Oostra BA
    Neurobiol Dis; 2011 Jun; 42(3):311-7. PubMed ID: 21316452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fragile X mice have robust mGluR5-dependent alterations of social behaviour in the Automated Tube Test.
    de Esch CE; van den Berg WE; Buijsen RA; Jaafar IA; Nieuwenhuizen-Bakker IM; Gasparini F; Kushner SA; Willemsen R
    Neurobiol Dis; 2015 Mar; 75():31-9. PubMed ID: 25562659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibiting mGluR5 activity by AFQ056/Mavoglurant rescues circuit-specific functional connectivity in Fmr1 knockout mice.
    Zerbi V; Markicevic M; Gasparini F; Schroeter A; Rudin M; Wenderoth N
    Neuroimage; 2019 May; 191():392-402. PubMed ID: 30807820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of activity-mediated spine dynamics and learning impairment in a mouse model of Fragile X syndrome.
    Boda B; Mendez P; Boury-Jamot B; Magara F; Muller D
    Eur J Neurosci; 2014 Apr; 39(7):1130-7. PubMed ID: 24712992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fragile X syndrome: a preclinical review on metabotropic glutamate receptor 5 (mGluR5) antagonists and drug development.
    Pop AS; Gomez-Mancilla B; Neri G; Willemsen R; Gasparini F
    Psychopharmacology (Berl); 2014 Mar; 231(6):1217-26. PubMed ID: 24232444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of Phosphodiesterase 2A Activity in the Pathophysiology of Fragile X Syndrome.
    Maurin T; Melancia F; Jarjat M; Castro L; Costa L; Delhaye S; Khayachi A; Castagnola S; Mota E; Di Giorgio A; Servadio M; Drozd M; Poupon G; Schiavi S; Sardone L; Azoulay S; Ciranna L; Martin S; Vincent P; Trezza V; Bardoni B
    Cereb Cortex; 2019 Jul; 29(8):3241-3252. PubMed ID: 30137253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ICAM5 as a Novel Target for Treating Cognitive Impairment in Fragile X Syndrome.
    Pei YP; Wang YY; Liu D; Lei HY; Yang ZH; Zhang ZW; Han M; Cheng K; Chen YS; Li JQ; Cheng GR; Xu L; Wu QM; McClintock SM; Yang Y; Zhang Y; Zeng Y
    J Neurosci; 2020 Feb; 40(6):1355-1365. PubMed ID: 31882402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Environmental enrichment reveals effects of genotype on hippocampal spine morphologies in the mouse model of Fragile X Syndrome.
    Lauterborn JC; Jafari M; Babayan AH; Gall CM
    Cereb Cortex; 2015 Feb; 25(2):516-27. PubMed ID: 24046080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen.
    Henderson C; Wijetunge L; Kinoshita MN; Shumway M; Hammond RS; Postma FR; Brynczka C; Rush R; Thomas A; Paylor R; Warren ST; Vanderklish PW; Kind PC; Carpenter RL; Bear MF; Healy AM
    Sci Transl Med; 2012 Sep; 4(152):152ra128. PubMed ID: 22993295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.